Cas no 1404-26-8 (polymyxin B)

Polymyxin B is a cyclic polypeptide antibiotic derived from Bacillus polymyxa, primarily effective against Gram-negative bacteria. It acts by disrupting the bacterial cell membrane through interaction with lipopolysaccharides, leading to cell lysis. Polymyxin B is particularly notable for its activity against multidrug-resistant pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Its clinical utility is often reserved for severe infections when other treatments fail due to potential nephrotoxicity and neurotoxicity. The compound is typically administered intravenously or topically, depending on the infection site. Polymyxin B is often combined with other antibiotics to enhance efficacy and mitigate resistance development, making it a critical agent in combating resistant Gram-negative infections.
polymyxin B structure
polymyxin B structure
Product Name:polymyxin B
CAS No:1404-26-8
MF:C56H98N16O13
MW:1203.47673273087
CID:83659
PubChem ID:4868
Update Time:2025-10-28

polymyxin B Chemical and Physical Properties

Names and Identifiers

    • polymyxin B
    • POLYMYXIN B SULPHATE INJECTION
    • Aerosporin
    • Polimixina B
    • Polimixina B [INN-Spanish]
    • Polymixin B
    • Polymyxine B
    • Polymyxine B [INN-French]
    • Polymyxinum B
    • Polymyxinum B [INN-Latin]
    • UNII-J2VZ07J96K
    • Polymyxin E see Colistin
    • polymyxin B 2.5sulfate entahydrate
    • GTPL10338
    • IDI1_000732
    • AB00053527_02
    • SBI-0051486.P003
    • CHEMBL241797
    • KBioSS_001597
    • KBio2_001597
    • KBio1_000732
    • KBio2_006733
    • Spectrum2_000490
    • SCHEMBL7799155
    • NCGC00178768-01
    • KBioGR_000961
    • SPBio_000359
    • BSPBio_002197
    • Spectrum5_001331
    • KBio3_001697
    • Spectrum3_000549
    • DivK1c_000732
    • 1404-26-8
    • KBio2_004165
    • Spectrum4_000481
    • NINDS_000732
    • Spectrum_001117
    • NCGC00178768-03
    • Polymyxin B (base and/or unspecified salts)
    • WQVJHHACXVLGBL-UHFFFAOYSA-N
    • 4135-11-9
    • BRD-A08641215-065-04-8
    • CHEMBL4092980
    • 4,10-anhydro{N-[(6R)-6-methyloctanoyl]-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-phenylalanyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine}
    • CHEBI:8309
    • (6R)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide
    • Q27108044
    • N-[(2S)-4-Amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide
    • SCHEMBL136097
    • Inchi： 1S/C56H98N16O13/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80)
    • InChI Key： WQVJHHACXVLGBL-UHFFFAOYSA-N
    • SMILES： O=C1C(CC(C)C)NC(C(CC2C=CC=CC=2)NC(C(CCN)NC(C(CCNC(C(C(C)O)NC(C(CCN)NC(C(CCN)N1)=O)=O)=O)NC(C(CCN)NC(C(C(C)O)NC(C(CCN)NC(CCCCC(C)CC)=O)=O)=O)=O)=O)=O)=O

Computed Properties

  • Exact Mass: 1188.73000
  • Monoisotopic Mass: 1188.592106
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 20
  • Hydrogen Bond Acceptor Count: 22
  • Heavy Atom Count: 82
  • Rotatable Bond Count: 25
  • Complexity: 2010
  • Covalently-Bonded Unit Count: 2
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 10
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 574
  • XLogP3: -2.5

Experimental Properties

  • Density: g/cm3
  • Boiling Point: 1651 °C at 760 mmHg
  • Flash Point: 952.3 °C
  • PSA: 490.66000
  • LogP: 1.73180
  • Specific Rotation: 5461 -106.3° (1N HCl)

polymyxin B Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
DC Chemicals
DC10214-100 mg
Polymyxin B sulphate
 1404-26-8 >98%
100mg
 $100.0 2022-02-28
DC Chemicals
DC10214-250 mg
Polymyxin B sulphate
 1404-26-8 >98%
250mg
 $200.0 2022-02-28
DC Chemicals
DC10214-1 g
Polymyxin B sulphate
 1404-26-8 >98%
1g
 $400.0 2022-02-28
DC Chemicals
DC10214-100mg
Polymyxin B sulphate
 1404-26-8 >98%
100mg
 $100.0 2023-09-15
DC Chemicals
DC10214-250mg
Polymyxin B sulphate
 1404-26-8 >98%
250mg
 $200.0 2023-09-15
DC Chemicals
DC10214-1g
Polymyxin B sulphate
 1404-26-8 >98%
1g
 $400.0 2023-09-15
A2B Chem LLC
AE37278-100mg
Polymyxin B
 1404-26-8 91%
100mg
 $65.00 2024-04-20
A2B Chem LLC
AE37278-500mg
Polymyxin B
 1404-26-8 91%
500mg
 $95.00 2024-04-20

polymyxin B Related Literature

Related Categories

Additional information on polymyxin B

Polymyxin B: A Comprehensive Overview

Polymyxin B, with the CAS number 1404-26-8, is a member of the polymyxins group of antibiotics, which are cyclic peptides with potent activity against Gram-negative bacteria. These compounds were first isolated from Bacillus polymyxa and have since been widely studied for their unique mechanisms of action and therapeutic potential. Polymyxin B is particularly notable for its ability to combat multidrug-resistant (MDR) pathogens, making it a critical component in the arsenal against antibiotic resistance.

The chemical structure of polymyxin B consists of a cyclic peptide backbone with a lipid tail, which contributes to its ability to interact with bacterial membranes. Recent studies have highlighted the importance of understanding the molecular interactions between polymyxin B and bacterial lipopolysaccharides (LPS). Research published in Nature Microbiology in 2023 demonstrated that polymyxin B disrupts LPS integrity by binding to lipid A, leading to membrane destabilization and bacterial cell death. This mechanism underscores the drug's effectiveness against MDR strains such as Pseudomonas aeruginosa and Acinetobacter baumannii.

In clinical settings, polymyxin B is often used as a last-line therapy for infections caused by carbapenem-resistant Enterobacteriaceae (CRE) and other highly resistant pathogens. However, its use is not without challenges. The emergence of resistance to polymyxins has become a growing concern, particularly due to the acquisition of plasmid-mediated resistance genes such as mcr-1. A study in The Lancet Infectious Diseases reported that the prevalence of polymyxin resistance has increased significantly in recent years, driven by the overuse of antibiotics in both clinical and agricultural settings.

To address these challenges, researchers are exploring novel strategies to enhance the efficacy of polymyxin B. One promising approach involves combining polymyxins with other antimicrobial agents to synergistically combat bacterial infections. For instance, a 2023 study in Antimicrobial Agents and Chemotherapy demonstrated that co-administration of polymyxin B with β-lactams significantly reduced the minimum inhibitory concentration (MIC) required for bacterial eradication. Additionally, advancements in drug delivery systems, such as nanoparticles and liposomes, are being investigated to improve the pharmacokinetics and reduce toxicity associated with polymyxins.

Beyond its clinical applications, polymyxin B has also been studied for its potential in non-traditional therapeutic areas. Recent research has explored its anti-inflammatory properties, which may be harnessed to treat conditions such as sepsis and acute respiratory distress syndrome (ARDS). A study published in Biochemical Pharmacology revealed that polymyxins can modulate toll-like receptor (TLR) signaling pathways, thereby reducing cytokine storm and inflammatory responses in infected patients.

In conclusion, polymyxin B remains a vital tool in combating antibiotic resistance, particularly against Gram-negative pathogens. Its unique mechanism of action, combined with ongoing research into resistance mechanisms and novel therapeutic strategies, positions it as a cornerstone in modern antimicrobial therapy. As the global fight against antibiotic resistance intensifies, continued investment in research and development will be essential to optimize the use of polymyxins like CAS No. 1404-26-8 and ensure their efficacy for future generations.

1404-26-8 (polymyxin B) Related Products

Recommended suppliers
PRIBOLAB PTE.LTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
PRIBOLAB PTE.LTD
Shandong Jing Kun Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Jing Kun Chemical Co.,Ltd.
Yunnanjiuzhen
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Yunnanjiuzhen
Zhejiang Brunova Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Zhejiang Brunova Technology Co., Ltd.
Shandong Feiyang Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Feiyang Chemical Co., Ltd